RxDoctor Payments Data

Anthony Gunawan, MD

Cardiovascular Disease · Houston, TXNPI 1386671386

Payments from drug & device makers

$30,025in general payments, 2019–2025

Across 862 payments — averaging $34.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Johnson & Johnson$3K
  • Novo Nordisk$3K
  • Boston Scientific$2K
  • Amgen$2K
  • Medtronic$1K
  • plus $14K from 52 others

What the payments were for

  • Consulting fees$1,4815%
  • Speaking & faculty fees$170%
  • Travel & lodging$8043%
  • Food & beverage$27,57592%
  • Education$1490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,025 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$262,483
Medicare patients
783
Services billed
3,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban482$565,829
XareltoRivaroxaban309$347,180
EntrestoSacubitril/Valsartan70$107,078
Repatha SureclickEvolocumab86$92,534
OzempicSemaglutide44$84,368
JardianceEmpagliflozin49$73,186
FarxigaDapagliflozin Propanediol58$66,826
BrilintaTicagrelor46$55,156
MounjaroTirzepatide38$47,365
JanuviaSitagliptin Phosphate24$32,176
TrulicityDulaglutide17$22,349
Telmisartan497$15,769
Metoprolol Succinate737$11,686
VascepaIcosapent Ethyl13$8,721
Atorvastatin Calcium859$7,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$324$565,829482 claims
Johnson & JohnsonXarelto$2,982$347,180309 claims
AstraZenecaFarxiga, Brilinta$5,102$121,983104 claims
NovartisEntresto$972$107,07870 claims
Novo NordiskOzempic$2,619$84,36844 claims
Boehringer IngelheimJardiance$632$73,18649 claims
Lilly USA, LLCMounjaro, Trulicity$338$69,71455 claims
MerckJanuvia$1,067$32,17624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →